menu
    • menu
    [{"orgOrder":0,"company":"Eisai","sponsor":"GHIT","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Fosravuconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ GHIT","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ GHIT"},{"orgOrder":0,"company":"GHIT Fund","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Fosravuconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GHIT Fund","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"GHIT Fund \/ Eisai","highestDevelopmentStatusID":"8","companyTruncated":"GHIT Fund \/ Eisai"},{"orgOrder":0,"company":"Eisai","sponsor":"Sato Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Fosravuconazole","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eisai \/ Sato Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Eisai \/ Sato Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Fosravuconazole

    Menu

    Fosravuconazole

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eisai

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eisai

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosravuconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Sato Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Eisai Partners with Sato Pharma to Commercialize Fosravuconazole in Asia, Oceania

                            Details : Under this agreement, Eisai exclusively licenses the intellectual property rights of Nailin (fosravuconazole) to Sato Pharma. It is indicated for the treatment of onychomycosis.

                            Brand Name : Nailin

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : Fosravuconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Sato Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GHIT Fund

                            Country arrow
                            2024 ACI Convention
                            Not Confirmed

                            GHIT Fund

                            Country arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosravuconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Eisai

                            Deal Size : $11.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Eisai’s Initiatives For Developing New Medicines For Neglected Tropical Diseases And Malaria And Commitment ...

                            Details : The funding will be used in the development of Eisai's in-house developed agent E1224 (fosravuconazole) in Sudan for the treatment of mycetoma in partnership with the non-profit organization Drugs for Neglected Diseases initiative (DNDi).

                            Brand Name : E1224

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 25, 2023

                            Lead Product(s) : Fosravuconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Eisai

                            Deal Size : $11.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eisai

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eisai

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosravuconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : GHIT

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            A Total of Approximately 400 Million Yen Investment in Eisai, Ehime University, DNDi and Others for New Drug a...

                            Details : The funding aims to bridge the gap between outcome of the E1224, fosravuconazole's randomized clinical trial (RCT), and access to fosravuconazole for treatment of eumycetoma in Sudan.

                            Brand Name : E1224

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 30, 2023

                            Lead Product(s) : Fosravuconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : GHIT

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth